0001209191-17-019645.txt : 20170309
0001209191-17-019645.hdr.sgml : 20170309
20170309164831
ACCESSION NUMBER: 0001209191-17-019645
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170209
FILED AS OF DATE: 20170309
DATE AS OF CHANGE: 20170309
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adverum Biotechnologies, Inc.
CENTRAL INDEX KEY: 0001501756
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 205258327
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1035 O'BRIEN DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 650-272-6269
MAIL ADDRESS:
STREET 1: 1035 O'BRIEN DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
FORMER COMPANY:
FORMER CONFORMED NAME: Avalanche Biotechnologies, Inc.
DATE OF NAME CHANGE: 20100921
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cheng Jennifer C.
CENTRAL INDEX KEY: 0001698816
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36579
FILM NUMBER: 17679058
MAIL ADDRESS:
STREET 1: C/O ADVERUM BIOTECHNOLOGIES, INC.
STREET 2: 1035 O'BRIEN DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2017-02-09
0
0001501756
Adverum Biotechnologies, Inc.
ADVM
0001698816
Cheng Jennifer C.
C/O ADVERUM BIOTECHNOLOGIES, INC.
1035 O'BRIEN DRIVE
MENLO PARK
CA
94025
0
1
0
0
General Counsel
Common Stock
107713
D
Stock Option (Right to Buy)
40.28
2025-06-04
Common Stock
15000
D
Stock Option (Right to Buy)
4.09
2026-09-19
Common Stock
35000
D
Stock Option (Right to Buy)
2.70
2027-02-08
Common Stock
72000
D
25% of the shares subject to the option vested and became exercisable on June 5, 2016, and the remaining shares vest in 36 successive, equal installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
25% of the shares subject to the option vest and become exercisable on September 20, 2017, and the remaining shares vest in 36 successive, equal installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
25% of the shares subject to the option vest and become exercisable on February 9, 2018, and the remaining shares vest in 36 successive, equal installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
/s/ Jennifer C. Cheng, Ph.D., J.D.
2017-03-09